Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting (GlobeNewswire) - Oct 1, 2024 - P1/2 | N=55 | ReSPECT-GBM (NCT01906385) | Sponsor: Plus Therapeutics | "Plus Therapeutics, Inc...presented an update on the ongoing ReSPECT-GBM Phase 1/2 clinical trial, evaluating the Company's lead asset Rhenium (186Re) Obisbemeda for the treatment of recurrent glioblastoma....Rhenium (186Re) Obisbemeda continues to show a favorable safety profile in the 42 enrolled patients; one dose-limiting toxicity (hemiplegia) has been reported, which was observed in Cohort 8 (41.5 mCi and 16.3 mL)....To date, 88.9% of Phase 2 patients met key CED drug delivery parameters shown to correlate with overall survival, achieving a tumor absorbed dose >100 Gy and radiation coverage of >70%....In terms of objective tumor response based on quantitative image analysis, a statistically significant reduction in tumor volume rate change was seen in tumors receiving > 100 Gy absorbed dose (n=11 patients analyzed to date, p<0.005)."
P1/2 data • Glioblastoma
|